🇺🇸 Diprivan in United States

FDA authorised Diprivan on 2 October 1989 · 1,969 US adverse-event reports

Marketing authorisations

FDA — authorised 2 October 1989

  • Application: NDA019627
  • Marketing authorisation holder: FRESENIUS KABI USA
  • Status: supplemented

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaphylactic Shock — 477 reports (24.23%)
  2. Hypotension — 307 reports (15.59%)
  3. Bronchospasm — 186 reports (9.45%)
  4. Cardiac Arrest — 179 reports (9.09%)
  5. Drug Ineffective — 176 reports (8.94%)
  6. Tachycardia — 149 reports (7.57%)
  7. Renal Failure — 129 reports (6.55%)
  8. Blood Pressure Decreased — 125 reports (6.35%)
  9. Shock — 125 reports (6.35%)
  10. Erythema — 116 reports (5.89%)

Source database →

Diprivan in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Diprivan approved in United States?

Yes. FDA authorised it on 2 October 1989; FDA has authorised it.

Who is the marketing authorisation holder for Diprivan in United States?

FRESENIUS KABI USA holds the US marketing authorisation.